ES2566729T3 - Tetrahidroquinolinas sustituidas - Google Patents

Tetrahidroquinolinas sustituidas Download PDF

Info

Publication number
ES2566729T3
ES2566729T3 ES06840909.3T ES06840909T ES2566729T3 ES 2566729 T3 ES2566729 T3 ES 2566729T3 ES 06840909 T ES06840909 T ES 06840909T ES 2566729 T3 ES2566729 T3 ES 2566729T3
Authority
ES
Spain
Prior art keywords
naril
hal
nnr2
nheteroaryl
nxr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06840909.3T
Other languages
English (en)
Spanish (es)
Inventor
Kai Schiemann
Ulrich Emde
Dirk Finsinger
Christiane Amendt
Nina Heiss
Frank Zenke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2566729T3 publication Critical patent/ES2566729T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES06840909.3T 2005-06-13 2006-05-17 Tetrahidroquinolinas sustituidas Expired - Lifetime ES2566729T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102005027170 2005-06-13
DE102005027170A DE102005027170A1 (de) 2005-06-13 2005-06-13 Substituierte Tetrahydrochinoline
PCT/EP2006/004656 WO2007054138A1 (de) 2005-06-13 2006-05-17 Substituierte tetrahydrochinoline

Publications (1)

Publication Number Publication Date
ES2566729T3 true ES2566729T3 (es) 2016-04-15

Family

ID=36699028

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06840909.3T Expired - Lifetime ES2566729T3 (es) 2005-06-13 2006-05-17 Tetrahidroquinolinas sustituidas

Country Status (15)

Country Link
US (1) US7893082B2 (enExample)
EP (1) EP1891076B1 (enExample)
JP (1) JP5180070B2 (enExample)
KR (1) KR20080030015A (enExample)
CN (2) CN102010416A (enExample)
AR (1) AR054616A1 (enExample)
AU (1) AU2006312800B2 (enExample)
BR (1) BRPI0611613A2 (enExample)
CA (1) CA2611889C (enExample)
DE (1) DE102005027170A1 (enExample)
ES (1) ES2566729T3 (enExample)
MX (1) MX2007015782A (enExample)
RU (1) RU2007147925A (enExample)
WO (1) WO2007054138A1 (enExample)
ZA (1) ZA200800365B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
DE102007013855A1 (de) * 2007-03-20 2008-09-25 Merck Patent Gmbh Substituierte Tetrahydrochinoline
WO2009052288A1 (en) 2007-10-19 2009-04-23 Schering Corporation Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity
US8278454B2 (en) * 2007-12-18 2012-10-02 MERCK Patent Gesellschaft mit beschränkter Haftung Process for preparing tetrahydroquinoline derivatives
US12275729B2 (en) 2017-11-01 2025-04-15 Merck Sharp & Dohme Llc Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
EP4269392A4 (en) 2020-12-25 2025-01-29 Toray Industries, Inc. TETRAHYDROQUINOLINE DERIVATIVE AND MEDICAL USE THEREOF
EP4545079A4 (en) 2022-06-24 2026-06-03 Toray Industries THERAPEUTIC OR PROPHYLACTIC AGENT FOR AMYOTROPHIC LATERAL SCLEROSIS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998027093A1 (en) * 1996-12-18 1998-06-25 Eli Lilly And Company Combinatorial process for preparing hydrofuroquinoline libraries
US6288075B1 (en) * 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
US7250423B2 (en) 2001-09-24 2007-07-31 Chao-Jun Li Methods for synthesizing heterocycles and therapeutic use of the heterocycles for cancers
WO2005016255A2 (en) 2003-07-16 2005-02-24 Ligand Pharmaceuticals Incorporated Substituted tetrahydroquinolines, phenylacetic acids and benzoic acids as hepatocyte nuclear factor 4 (hnf-4 ) modulator compounds
DK1761515T3 (da) * 2003-12-20 2009-02-16 Merck Patent Gmbh 2-(hetero-)aryl-substituerede tetrahydroquinolinderivater
SE0400285D0 (sv) * 2004-02-10 2004-02-10 Astrazeneca Ab Pyrroloquinoline and piperidoquinoline derivatives, preparation thereof, compositions containing them and uses thereof
RU2384571C2 (ru) * 2004-04-28 2010-03-20 Такеда Фармасьютикал Компани Лимитед Конденсированное хинолиновое производное и его применение
DE102005027168A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinoline
DE102005027169A1 (de) * 2005-06-13 2006-12-14 Merck Patent Gmbh Tetrahydrochinolinderivate
KR20090020702A (ko) * 2006-06-19 2009-02-26 메르크 파텐트 게엠베하 다형체 및 방법

Also Published As

Publication number Publication date
DE102005027170A1 (de) 2006-12-14
JP2008545803A (ja) 2008-12-18
AU2006312800A1 (en) 2007-05-18
WO2007054138A1 (de) 2007-05-18
EP1891076A1 (de) 2008-02-27
CN101198613A (zh) 2008-06-11
AR054616A1 (es) 2007-07-04
CN102010416A (zh) 2011-04-13
CA2611889C (en) 2013-05-14
EP1891076B1 (de) 2016-01-27
ZA200800365B (en) 2009-05-27
RU2007147925A (ru) 2009-07-20
US7893082B2 (en) 2011-02-22
CA2611889A1 (en) 2007-05-18
JP5180070B2 (ja) 2013-04-10
MX2007015782A (es) 2008-02-22
KR20080030015A (ko) 2008-04-03
AU2006312800B2 (en) 2011-08-25
BRPI0611613A2 (pt) 2010-09-21
US20080194615A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
ES2548525T3 (es) Derivados de tiazol para el tratamiento del cáncer
WO2022087375A1 (en) Novel heterocyclic compounds
ES2644128T3 (es) Derivados de benzonitrilo como inhibidores de quinasa
ES2392475T3 (es) Derivados de piperidina y piperazina para el tratamiento de tumores
ES2532139T3 (es) Derivados de piridazinona
ES2579981T3 (es) Derivados de triazolopirazina
ES2654464T3 (es) Derivados de quinazolinona como inhibidores de PARP
US20050137185A1 (en) Combinations of drugs for the treatment of neoplasms
WO2022087371A1 (en) Novel bicyclic compounds
ES2612686T3 (es) Derivados de quinoxalina
US20060264384A1 (en) Compositions and methods for treatment for neoplasms
ES2542647T3 (es) Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos
US20040116407A1 (en) Combinations of drugs for the treatment of neoplasms
AU2004309028A1 (en) 2-(hetero)-aryl-substituted tetrahydroquinoline derivatives
US20050054708A1 (en) Combinations of drugs for the treatment of neoplasms
WO2004006849A2 (en) Combinations of drugs for the treatment of neoplasms
US20110177060A1 (en) Iap bir domain binding compounds
AU2018317789B2 (en) Stable lyophilisates comprising 5,10-methylene-(6R)-tetrahydrofolic acid and a dicarboxylic acid
US20250114488A1 (en) Psma-targeted radiopharmaceuticals and checkpoint inhibitor combination therapy
WO2004007676A2 (en) Combination therapy for the treatment of neoplasms
IL323688A (en) PSMA-targeted radiopharmaceuticals and combination therapy with DNA damage response inhibitors
ES2434247T3 (es) Formas polimórficas novedosas de dihidrogenofosfato de 6-(1-metil-1H-pirazol-4-il)-2-{3-[5-(2-morfolin-4-il-etoxi)-pirimidin-2-il]-bencil}-2H-piridazin-3-ona y procesos de fabricación de las mismas
WO2005117847A2 (en) Methods and compounds for the treatment of neoplasms
HK1101547A (en) Combinations of drugs for the treatment of neoplasms